Palliative Treatment of Advanced Cervical Cancer with Radiotherapy and Thai Herbal Medicine as Supportive Remedy - Analysis of Survival

  • Pesee, Montien (Division of Radiotherapy, Department of Radiology, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University) ;
  • Kirdpon, Wichit (Division of Nuclear Medicine, Department of Radiology, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University) ;
  • Puapairoj, Anucha (Department of Pathology, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University) ;
  • Kirdpon, Sukachart (Department of Pediatrics, Faculty of Medicine, Khon Kaen University) ;
  • Prathnadi, Pongsiri (Department of Surgery, Faculty of Medicine, Chiang Mai University)
  • 발행 : 2013.03.30


Background: To evaluate outcomes using a Thai herbal medicine, Vilac Plus (G716/45) with standard radiotherapy in comparison with historic controls from literature reports of the results of treatment in stage IIIB cervical cancer. Materials and Methods: Between March 2003 and June 2005, thirty patients with advanced cervical cancer stage IIIB-IV who had a poor performance status were treated by palliative radiotherapy along with an adjuvant daily dose of 15-30 ml of Thai herbal tonic solution (Vilac Plus G716/45) administered orally three times after meals as an additional supportive therapy. The results were analyzed from the aspect of the overall survival rates with curves estimated by the Kaplan-Meier method. Results:.The median follow -up time for stage IIIB was 4.2 years with a range of 7.9 months - 6.1 years. The overall 1, 3, and 5 year survival rates for stage IIIB were 88%, 60% and 52%. Conclusions: The overall 5 year survival rate for stage IIIB with a poor performance status was 52% when compared with 34-54.8% for historic controls. The combined complementary palliative radiotherapy (CCPR) had low rates of radiation morbidity. It was a simple technique and feasible for developing countries. The pilot study was limited by the small number of patients and further research will be necessary to assess interrelated and confounding factors in treatment of cervical cancer patients.


  1. Arai T, NakanoT, Morita S, et al (1992). High dose rate remote afterloading intracavitary radiation therapy for cancer of the uterine cervix. A 20-year experience. Cancer, 69, 175-80.<175::AID-CNCR2820690129>3.0.CO;2-B
  2. Amadi PP, Suntorntanasat T (2004). Analytical report on herbal tonic solution.(G716/45). An analytical report. Thailand Institute of Scientific and Technological Research, 1-3.
  3. Barnett M (2001). Overview of complementary therapies in cancer care. In: Textbook of Integrated Cancer Care. Holistic, complementary, and Creative approaches. Barraclough J, ed. NewYork : Oxford University Press 1-17.
  4. Bermudez RS, Huang K, Hsu IC (2010). Cervical cancer. In:Handbook of evidence- based radiation oncology, second edition. Hansen EK, Roach III M , eds. New York: Spinger, 499-512.
  5. Banjerdpongchai R, Kongtawelert P (2011). Ethanolic extract of fermented thunb induced human leukemic HL-60 and Molt-4 Cell apoptosis via oxidative stress and mitochondrial pathway. Asian Pac J Cancer Prev, 12, 2871-4.
  6. Cherng JM, Shieh DE, Chiang W, et al (2007). Chemopreventive effects of minor dietary constitutents in common foods on human cancer cells. Bioscience, Biotechnology and Biochemistry, 71, 1500-4.
  7. Chang JS, Chiang LC, Chen CC, et al (2001). Antileukemic activity of bidens pilosa L, var. minor (Blume) sherff and Houttuynia cordata thunb. Am J Clin Med, 29, 303-12.
  8. Green JA, Kirwan JM, Tierney JF, et al (2001). Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet, 358, 781-6.
  9. Hayashi K, Kamiya M, Hayashi T (1995). Virucidal effects of the steam distillate from Houttuynia cordata and its components on HSV-1, influenza virus and HIV. Planta Med, 61, 237-41.
  10. International Federation of Gynecologists and Obstetricians (1995). Staging announcement: FIGO staging of gynecologic cancers: cervical and vulva. Int J Gynecol Cancer, 5, 319.
  11. Kim HW, Kim BK (1999). Biomedicinal triterpenoids of Ganoderma lucidum (Aphyllophoromycetideae). Int J Med Mushroom, 1, 121-38.
  12. Lorvidhaya V, Tonusin A, Changwiwit W, et al (2000). High dose rate afterloading brachytherapy in carcinomas of the cervix: an experience of 1992 patients. Int J Radiat Oncol Biol Phys, 46, 1185-91.
  13. Murosaki S, Muroyama K, Yamamoto Y, et al (2000). Antitumor effect of heat-killed Lactobacillus plantarum L-137 through restoration of impaired interleukin-12 production in tumorbearing mice. Cancer Immunother, 49, 157-64.
  14. Moss RW (2007). Do antioxidants interfere with radiation therapy for cancer. Integr Cancer Ther, 6, 281-92.
  15. Murakami A, Jiwajinda S, Koshimizu K, et al (1995). Screening for in vitro anti-tumor promoting activities of edible plant from Thailand. Cancer Letters, 95, 139-14.
  16. Matsuzaki T (1998). Immunomodulation by treatment with Lactobacillus casei strain shirota. Int J Food Microbiol, 41, 133-40.
  17. Okawa T, Niibe H, Arai T, et al (1993). Effect of LC 9018 combined with radiation therapy on carcinoma of the uterine cervix. A phase III, multicenter, randomized, controlled study. Cancer, 72, 1949-54.<1949::AID-CNCR2820720626>3.0.CO;2-W
  18. Phillippe D, Michel P (2006). In Vitro study of Vilac Plus analysis. Kirial International laboratories KRL Test (SPIRAL-No. Patent FR 2.642.526), 3 rue des Mardors 21560 COUTERNON, France, 1-4.
  19. Petsuksiri J, Jaishuen A, Pattaranutaporn P, et al (2012). Advanced imaging applications for locally advanced cervical cancer. Asian Pac J Cancer Prev, 13, 1713-8.
  20. Pesee M, Kirdpon W, Puapairoj A, et al (2007). Palliative treatment of advanced cervical cancer with radiotherapy and Thai herbal medicine as supportive remedy. Asean J Radiology, 13, 171-84.
  21. Pesee M, Krusun S, Padoongcharoen P (2010). High dose rate Cobalt-60 afterloading intracavitary therapy of the uterine cervical carcinoma in Srinagarind hospital, Analysis of survival. Asian Pac J Cancer Prev, 11, 1469-71.
  22. Pomros P, Sriamporn S, Tangvoraphonkchai V, et al (2007). Factors affectng survival of cervical cancer patients treated at the radiation unit of srinagarind hospital, Khon Kaen university, Thailand. Asian Pac J Cancer Prev, 8, 297-300.
  23. Potter R, Georg P, Dimopoulos JCA, et al (2011). Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol, 100, 116-23.
  24. Rose PG, Ali S, Watkins E, et al (2007). Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a gynecology group study, J Clin Oncol, 25, 2804-10.
  25. Sriamporn S, Swaminathan R, Parkin DM, et al (2004). Lossadjusted surivival of cervix cancer in Khon Kaen, Northeast Thailand. Bri J Cancer, 91, 106-10.
  26. Simone CB 2nd, Simone NL, Simone V, et al (2007). Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med, 13, 22-8.
  27. Suntorntanasat T, Banchonglikitkul C, Klungsupaya P, et al (2003). Acute oral toxicity test herbal tonic solution (G716/45). An analytical report. Thailand Institute of Scientific and Technological Research, 1-8.
  28. Sliva D (2003). Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther, 2, 358-64.
  29. Thomas MG (2000). Concurrent chemotherapy and radiation for locally advanced cervical cancer: the new standard of care. Seminar in Radiation Oncology, 10, 44-50.
  30. Toita T, Kitagawa R, Hamano T, et al (2012). Feasibility and acute toxicity of concurrent chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/$m^2$ weekly cisplatin for Japanese patients with cervical cancer: results of a multi-institutional phase 2 study (JGOG). Int J Gynecol Cancer, 22, 1420-6.
  31. Van der Hem LG (1995). Ling Zhi-8. Studies of a new immuno modulating agent. Transplantation, 60, 438-43.
  32. Wang SY (1997). Anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T-lymphocytes. Int J Cancer, 70, 699-705.<699::AID-IJC12>3.0.CO;2-5
  33. Wong F CS, Tung SY, Leung TW, et al (2003). Treatment results of high-dose –rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens. Int J Radiation Oncology Biol Phys, 55, 1254-64.
  34. Wu QP, Xie YZ, Li SZ, et al (2006). Tumor cell adhesion and integrin expression affected by Ganoderma lucidum. Enzyme Microbial Technol, 40, 32-41.

피인용 문헌

  1. Treatment Interruption During Concurrent Chemoradiotherapy of Uterine Cervical Cancer; Analysis of Factors and Outcomes vol.15, pp.14, 2014,
  2. Comparisons between the KKU-Model and Conventional Rectal Tubes as Markers for Checking Rectal Doses during Intracavitary Brachytherapy of Cervical Cancer vol.15, pp.15, 2014,